Truveta Strengthens Regulatory Science Arm with Top Epidemiologist

Event summary

  • Truveta appointed John D. Seeger, PharmD, DrPH, FISPE as Senior Vice President of Evidence Services on February 9, 2026.
  • Seeger brings over 30 years of experience in pharmacoepidemiology and regulatory science.
  • He previously led epidemiology teams at RTI-HS and Optum, and held academic roles at Harvard.
  • Seeger's role will focus on advancing Truveta's regulatory-grade evidence services for life science partners.
  • Truveta's data is owned by a consortium of 39 U.S. health systems.

The big picture

Truveta's appointment of Seeger underscores the growing importance of real-world evidence in regulatory decision-making. As life science companies increasingly rely on observational data for drug approvals and post-market surveillance, Truveta is positioning itself as a key provider of scalable, high-quality evidence. The move also highlights the strategic value of health system-owned data in driving regulatory science forward.

What we're watching

Regulatory Credibility
How Seeger's appointment will accelerate Truveta's adoption by regulatory bodies and life science companies.
Data Utilization
The pace at which Truveta can scale its evidence services to meet growing demand for real-world data in drug development.
Competitive Positioning
Whether Truveta can maintain its lead in regulatory-grade evidence as competitors invest in similar capabilities.